Please try another search
Investigator-Sponsored Phase 2 Study Demonstrated Positive Results for VOXZOGO in Children with HypochondroplasiaNew Analyses Highlight VOXZOGO 7-year Data and Improvement on Quality of Life in...
SAN RAFAEL, Calif. - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced the appointment of Cristin Hubbard as its new executive vice president and chief commercial officer, effective May 20, 2024....
Investing.com – Swiss-based Roche Holding's bumper offer to acquire Spark Therapeutics on Monday propped up the healthcare sector and fueled speculation on Wall Street that more merger activity...
BioMarin Pharmaceutical Inc (NASDAQ:CRSP) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks hereCRISPR Therapeutics’ loss per share...
BioMarin Pharmaceutical Inc. (NASDAQ:EBS) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Is BMRN going up? Or down? Predict to see...
Sarepta Therapeutics On Monday April 25, 2016 Sarepta Therapeutics (NASDAQ:SRPT) had a FDA advisory panel shoot down its drug Eteplirsen, used to treat patients with Duchenne Muscular Dystrophy --...
Instrument Type
Region
Sector
Industry
Date
Category
Provider